Case Discussions on Improving Outcomes in Neovascular AMD: Applying Research to Practice (Archived CME Webcast)

This educational activity has expired. You will not be able to claim credit for this activity.

Activity Description

Although the treatment of neovascular age-related macular degeneration (nAMD) has made significant strides in the last several years, long-term visual acuity potential among affected populations still suffers due to delayed diagnosis and a high treatment burden leading to suboptimal patient adherence. Research demonstrates that earlier diagnosis of conversion from dry to wet age-related macular degeneration results in the best long-term visual outcomes. Although fixed, frequent dosing is also the gold standard for achieving and maintaining the best possible vision, accumulating research demonstrates that individualized dosing according to disease activity and fluid type can reduce the burden of treatment while maintaining vision. This approach is predicated on careful monitoring of retinal fluid on optical coherence tomography, which has been complicated by the coronavirus disease 2019 pandemic. Home monitoring of fluid dynamics has the potential to identify disease activity in real time while keeping vulnerable patients safer at home. In addition, newer anti–vascular endothelial growth factor agents have prolonged action, potentially enabling fewer injection visits compared with older agents. In this educational activity, experts in nAMD will discuss strategies for reducing the treatment burden in nAMD while identifying and treating fluid in an individualized manner. The desired results of this educational activity are for retina specialists and other ophthalmologists to use evidence-based diagnostic and treatment strategies for nAMD that minimize treatment burden while maximizing vision and quality of life outcomes for patients.

Target Audience

This educational activity is intended for retina specialists and other ophthalmologists who treat patients with neovascular age-related macular degeneration.

Learning Objectives

Upon completion of this activity, participants will be better able to:

    • Design and implement strategies for earlier diagnosis of conversion from dry to wet age-related macular degeneration
    • Interpret comparative clinical trial data for approved treatments for neovascular age-related macular degeneration
    • Develop individualized treatment strategies for patients with neovascular age-related macular degeneration that optimize efficacy and safety while minimizing injection burden
    • Incorporate recent clinical trial data into communication strategies to enhance patient adherence to treatment for neovascular age-related macular degeneration
    Course summary
    Course opens: 
    12/14/2020
    Course expires: 
    12/31/2025

    Faculty

    imageDavid Eichenbaum, MD (Co-Chair)
    Collaborative Associate Professor of Ophthalmology
    Morsani College of Medicine
    University of South Florida
    Partner and Director of Research
    Retina Vitreous Associates of Florida
    Tampa, Florida
    imageCharles C. Wykoff, MD, PhD (Co-Chair)
    Director of Research
    Retina Consultants of Houston
    Deputy Chair for Ophthalmology
    Blanton Eye Institute
    Houston Methodist Hospital
    Houston, Texas

    Disclosure Policy Statement

    It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.

    Disclosures

    David Eichenbaum, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; EyePoint Pharmaceuticals; Genentech, Inc; Gyroscope; Kodiak Sciences Inc; and Regeneron Pharmaceuticals, Inc; Contracted Research: Alkahest, Inc; Allergan; Chengdu Kanghong Pharmaceutical Group Co Ltd; Gemini Therapeutics; Genentech, Inc; Gyroscope; Ionis Pharmaceuticals, Inc; IVERIC Bio; Kodiak Sciences Inc; NGM Biopharmaceuticals; Regeneron Pharmaceuticals, Inc; and Santen Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Allergan; EyePoint Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Clearside Biomedical, Inc; and Hemera Biosciences.

    Charles C. Wykoff, MD, PhD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Acucela Inc; Adverum; Alcon; Alimera Sciences; Allergan; Apellis Pharmaceuticals; Arctic Vision (Shanghai) Biotechnology Co, Ltd; Bausch & Lomb Incorporated; Bayer Corporation; Bionic Vision Technologies; Chengdu Kanghong Pharmaceutical Group Co Ltd; D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.; F. Hoffmann-La Roche Ltd; Genentech, Inc; Gyroscope; IVERIC Bio; Kodiak Sciences Inc; Merck & Co., Inc; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; ONL Therapeutics; Opthea; Oxurion NV; Palatin Technologies, Inc; PolyPhotonix; Recens Medical, Inc; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; Takeda Pharmaceuticals USA, Inc; and Thea Pharmaceuticals Limited; Contracted Research: Adverum; Aerie Pharmaceuticals, Inc; Aldeyra Therapeutics; Apellis Pharmaceuticals; Boehringer Ingelheim International GmbH; Chengdu Kanghong Pharmaceutical Group Co Ltd; Clearside Biomedical, Inc; F. Hoffmann-La Roche Ltd; Gemini Therapeutics; Genentech, Inc; GrayBug, Inc; Gyroscope; Ionic Pharmaceuticals, Inc; IVERIC bio; Kodiak Sciences Inc; Neurotech Pharmaceuticals; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Opthea; Outlook Therapeutics, Inc; Recens Medical, Inc; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; Santen Inc; Senju Pharmaceutical Co, Ltd; Taiwan Liposome Company, Ltd; and Xbrane Biopharma AB; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Regeneron Pharmaceuticals, Inc.

    New York Eye and Ear Infirmary of Mount Sinai Peer Review Disclosure

    Gennady Landa, MD, has no relevant commercial relationships to disclose.

    Editorial Support Disclosures

    Erika Langsfeld, PhD; Cynthia Tornallyay, RD, MBA, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.

    Disclosure Attestation

    The contributing physicians listed above have attested to the following:

    1. that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
    2. that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
    3. that all reasonable clinical alternatives will be discussed when making practice recommendations.

    Accreditation Statement

    image The New York Eye and Ear Infirmary of Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This educational activity was developed and implemented in collaboration with MedEdicus LLC.

    AMA Credit Designation Statement

    The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Grantor Statement

    This continuing medical education activity is supported through unrestricted educational grants from Novartis Pharmaceuticals Corporation and Notal Vision, Inc.

    Off-Label Discussion

    This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

    New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies

    https://www.nyee.edu/education/cme

    CME Provider Contact Information

    For questions about this activity, call 917-270-7571.

    To Obtain AMA PRA Category 1 Credit™

    To obtain AMA PRA Category 1 Credit™ for this activity, complete the pretest, view the webcast, and complete the post test and evaluation. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.

    Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, Novartis Pharmaceuticals Corporation, or Notal Vision, Inc.

    This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 232

    Please login or register to take this course.

    This educational activity has expired. You will not be able to claim credit for this activity.